Medivir Announces Start of Phase 1a Trial of the Hepatitis C Polymerase Inhibitor TMC649128

[Guest guest]

Medivir Announces Start of Phase 1a Trial of the Hepatitis C Polymerase

Inhibitor TMC649128

PR Newswire Europe (English) - Feb. 10, 2011

Medivir today announces the start of a phase 1a clinical trial with TMC649128

intended for the treatment of chronic hepatitis C virus infection. TMC649128 is

a nucleoside NS5B polymerase inhibitor that has already demonstrated an

attractive pre-clinical profile. It is anticipated that this profile would see

TMC649128 be used in combination with HCV directly acting antiviral agents,

given their high genetic barrier to resistance and antiviral activity across

multiple HCV genotypes.